Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need
Authors' conclusion
There is a scarcity of data on PROs in the subset of pituitary adenomas that is more difficult to treat, e.g., refractory and these patients are difficult to isolate from the total cohort. The patients' perspective on quality of life, therefore, remains largely unknown in refractory patients. Thus, PROs in refractory pituitary adenomas require adequate analysis using properly reported disease specific PROMs in large cohorts to enable appropriate interpretation for use in clinical practice.
Study context
- Population
- Patients with refractory hormone-producing pituitary adenomas (tumors resistant to primary therapy)20 studies
- Outcome
- Quality and outcomes of PROMs used in refractory hormone-producing pituitary adenomas
Methodological detailsthree databases searched, risk of bias by component approach, PROM reporting quality by ISOQOL criteria
- Three databases searched
- Risk of bias by component approach
- PROM reporting quality by ISOQOL criteria
Pooled result
As reported in the abstract
Different PROMs used
14
Disease-specific PROMs
4
General risk of bias score
median 33.5%
range 6–50%
ISOQOL score
median 46%
range 29–62%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →